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Abstract
Background: Female sex workers (FSWs) at substantial risk of HIV are potentially a suitable group for HIV prevention
trials including vaccine trials. Few HIV vaccine preparatory studies have been conducted among FSWs in Sub-Saharan
Africa (SSA); data are therefore limited on acceptability of vaccine trial procedures. We determined vaccination
completion and one-year retention among FSWs in Kampala, Uganda.
Methods: We conducted a prospective study that simulated a vaccine efficacy trial among HIV negative FSWs (18–49
years). Hepatitis B vaccine (Engerix B) was used to mimic an HIV vaccine product. Volunteers received 1ml intramuscular
injection at 0, 1 and 6months, and made additional visits (3 days post-vaccination and months 3, 9 and 12). They were
censored at that visit if diagnosed as HIV positive or pregnant. We collected socio-demographic, behavioral and clinical
data at baseline, 6 and 12months and fitted Poisson regression models with robust standard error to find factors
associated with vaccination completion and retention.
Results: We enrolled 290 volunteers (median age 27 years) of whom 230 reached a study end-point as follows: 7
became HIV infected, 11 became pregnant and 212 completed both the vaccination schedule and 12-month visit
giving a retention of 77.9% (212/272). Vaccination completion was 82.4%.
Non-retention at 1 year was more likely among those reporting symptoms of genital ulcer disease (GUD) in the past 3
months (IRR 1.90; 95% CI 1.09–3.32) and those < 35 years; (IRR 6.59; 95% CI 2.11–20.57). Non-completion of the
vaccination schedule was associated with being < 35 years (IRR 13.10; 95% CI 1.89–90.92, reporting GUD symptoms (IRR
3.02; 95% CI 1.71–5.33) and reporting consistent condom use with new sexual partners (IRR 2.57; 95% CI 1.10–6.07).
Conclusions: FSWs are at substantial risk of HIV infection and yet willing to participate in HIV vaccine and prevention
research; young FSWs should be empowered, and those reporting GUD symptoms need close follow up to improve
participation in future HIV vaccine trials.
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Background
To date, several HIV-1 vaccine candidates have gone
through early phase clinical trials and shown acceptable
safety profiles [1, 2]. However, fewer vaccine candidates
have proceeded to phase III efficacy trials [1, 3], the RV144
trial conducted in Thailand being the first HIV vaccine effi-
cacy trial to provide evidence that a preventative HIV vac-
cine is possible [4, 5]. Although the 31% efficacy achieved
3.5 years after vaccination was insufficient for licensure, it
gave an opportunity to understand the immune correlates
of protection and improve this vaccine. The RV144
regimen was then modified and assessed for safety and
immunogenicity in the HVTN100 trial in South Africa.
The modified vaccine in HIVTN100 elicited sufficiently
high immune responses and, pre-specified immunological
go/no-go criteria were achieved leading to initiation of an
efficacy trial (HVTN702) [3, 6]. Several countries in Sub-
Saharan Africa (SSA) are now following volunteers in the
HVTN702 trial, assessing efficacy of one prime-boost
regimen and adjuvanted recombinant envelope protein
and HVTN705, assessing a mosaic adenovirus and clade C
envelope prime-boost regimen. With the on-going
HPTN084 trial comparing efficacy of long acting injectable
cabotegravir and oral PrEP (Tenofovir Disoproxyl Fumar-
ate /Emtricitabine), it is evident that several biomedical
HIV prevention products may soon be available; it is for
this reason that researchers in the International AIDS Vac-
cine Initiative (IAVI) network in SSA are preparing suitable
populations for future HIV prevention efficacy trials of
interventions such as long acting anti-retroviral drugs, pro-
tective antibodies and vaccines.
HIV vaccine preparatory studies to determine suitability
of populations, and inform recruitment and retention
strategies for future efficacy trials in SSA have followed up
cohorts of fishing communities, men who have sex with
men (MSM) and female sex workers (FSWs) where they
demonstrated retention rates of ≥80% [7, 8]. In addition,
studies of other HIV prevention interventions e.g. the
‘Partners PrEP trial which randomized discordant couples
to oral pre-exposure prophylaxis (PrEP) and Placebo, and
the Dapivirine ring study, which randomized high-risk
women to the dapivirine ring and placebo, both showed
efficacy of investigational products and retention of ≥85%
[9, 10]. In the HIV vaccine field, preparedness studies that
go beyond following up cohorts to conduct simulated vac-
cine efficacy trial (SiVET) procedures will inform accept-
ability of HIV vaccine research and retention among key
populations where the need for a vaccine remains acute.
Key populations have a high HIV incidence and preva-
lence [11, 12], making them suitable potential volunteers
in future vaccine efficacy trials. In SSA however there is
still limited data on SiVETs among key populations such
as FSWs whose social contexts may differ by region. In
Uganda for example, social structures include women
without capital who depend entirely on sex work for their
livelihood, those engaging in an institutionalized trade
often mediated by middlemen in entertainment facilities,
and the minority who are more financially independent
and earn from their own businesses as well as from sex
work [13]. In Uganda like many parts of SSA, sex work is
still criminalized and often times, the women encounter
police brutality, stigmatization from their communities,
and violence which is perpetrated by both clients and po-
lice [14, 15]. The women are also highly mobile [16] and,
coupled with the criminalization and discrimination they
face [17, 18], it is important to learn more about feasibility
of enrolling FSWs in Uganda, and if they would comply
with frequent study visits and vaccination procedures.
We conducted a SiVET using hepatitis B vaccine
(Engerix B) as a proxy for an HIV vaccine to assess volun-
teer retention and completion of a three-injection vaccin-
ation schedule among FSWs in Kampala, Uganda. The
study also provided an opportunity to develop and
strengthen site operational tools such as standard operating
procedures and quality management systems that will be
useful in the successful conduct of large efficacy trials.
Methods
Study design and procedures
We enrolled volunteers into a prospective study de-
signed to mimic the rigors of an HIV vaccine trial and
administered a licensed recombinant Hepatitis B vaccine
(ENGERIX-B™ GlaxoSmitheKline Biologicals Rixensart,
Belgium). We used Hepatitis B vaccine because it shares
some features with a potential HIV vaccine: the hepatitis
B vaccination schedule is similar to that of proposed
HIV vaccines and education messages to volunteers
would be similar given that Hepatitis B and HIV are
both chronic viral infections that share transmission
modes. Hepatitis B was also of potential benefit to the
volunteers as they are also at high risk for Hepatitis B
infection. We enrolled volunteers between August 2014
and May 2016, and each was scheduled to attend 9 visits
during a 12 month follow up period. At months 0, 1 and
6 they were scheduled to receive 1 ml of hepatitis B
vaccine by intramuscular injection in the deltoid muscle
of the non-dominant arm, and have two reactogenicity
assessments: at least 30 min and 3 days after each vaccin-
ation. Trained study nurses performed baseline clinical
assessments (including medical history and physical
examination) before giving the first vaccination dose and
administered questionnaires to collect study data. The
study pharmacist dispensed Hepatitis B vaccine to study
nurses who returned all used vials to the pharmacy. Vac-
cine accountability logs were used to document and
monitor vaccine use. The vaccine was stored in a 2–80 C
refrigerator and vaccine safety was ensured by monitor-
ing the cold chain daily and assessing volunteers for
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adverse events. Other study visits were scheduled at
months 3, 9 and 12 at which volunteers received HIV test-
ing and counselling (HTC), contraceptive services, syn-
dromic management of sexually transmitted infections
(STIs) and free health care for common illnesses. The
SiVET visits had scheduled windows as follows: vaccination
visits (±3 days), 3-day post vaccination visits (±1 day), all
other visits (±7 days) as shown below.
SiVET study visit schedule
Visit
1
Visit
2
Visit
3
Visit
4
Visit
5
Visit
6
Visit
7
Visit
8
Visit
9
Visit Month
(Study
Month = 28
days)
M0 M 1 M 3 M 6 M 9 M
12
Visit
Window
(Days)
± 1 ± 3 ± 1 ± 7 ± 3 ± 1 ± 7 ± 7
Vaccination
Visit
X X X
3-day post
vaccination
X X X
Study population and sampling
We conducted the study at the Good Health for Women
Project (GHWP) clinic of MRC/UVRI and LSHTM
Uganda Research Unit, located in a peri-urban community
in southern Kampala. Field workers conducted
mobilization activities with community peer leaders to
identify FSWs from commercial hotspots who were then
enrolled at the clinic irrespective of HIV status as has been
described by Vandepitte et al. [19]. They attended quarterly
follow up visits to receive HIV prevention and
treatment services which include HIV testing and
counselling (HTC); syndromic management for STIs;
contraception and, in addition, HIV care and treatment
for HIV positive volunteers.
Sample size determination
We estimated one-year retention in a simulated vaccine
efficacy trial to be 75% with a precision of ±5%.
Recruiting 290 participants was expected to provide 80%
power, at the 5% level of significance (two-sided).
We consecutively enrolled consenting HIV negative
volunteers who had been attending the GHWP cohort
for 6 to 18months and were ≥ 18 years, sexually active in
the 3 months before enrolment, not pregnant, willing to
use effective contraception until 3 months after the last
vaccination and not known to be allergic to yeast.
Volunteers were withdrawn from the study if they
became either HIV positive or pregnant, were no longer
interested in participating or were lost to follow up
(LTFU). Those who became HIV infected or pregnant
were censored at that study visit (i.e., taken off study to
complete their hepatitis B vaccine schedule outside the
study and receive further health care and treatment
provided at the GHWP clinic or referred as appropriate).
We defined LTFU as a volunteer not attending study
visits for six consecutive months, and was not known to
have died, moved out of the study area or withdrawn
from the study.
Volunteer retention
The study field team used phone calls to remind
volunteers about follow up visits and for those who needed
help to access the clinic, we used a project vehicle to pick
them up. Study volunteers received reimbursement of
4USD for time and transport costs when they attended
study visits. Free treatment for common illnesses and/ or
referral for those who needed specialized health care were
provided as needed and the study nurses always informed
them about their next scheduled date, which was
documented on their appointment card. Field workers kept
track of volunteers’ visits using a visit tracker and
volunteer visit calendars. When a volunteer missed one
visit, the field workers traced her and encouraged her to
come to the clinic for the next scheduled visit.
Laboratory methods
HIV testing was performed on serum using two or more
rapid antibody diagnostic tests administered serially as
follows: Determine screening test (Alere Medical Co. Ltd.,
Chuba, Japan), Statpak rapid confirmatory kit (Chembo
Diagnostics Systsem Inc., Medford, NY, USA) and Unigold
as tie breaker (Trinity Biotech Plc, Wicklow, Ireland).
Pregnancy tests were performed on urine using QuickVue
tests strips (Quidel Corporation, San Diego CA, USA).
Data collection
All data were collected using pre-designed interviewer
administered questionnaires.
The primary study outcomes for this manuscript were
vaccination completion and retention. We defined
vaccination completion as a volunteer receiving all three
doses of Hepatitis B vaccine and documented it as a
binary outcome (Yes/No).
Retention was defined as attendance of the month 12
visit by those who completed the 3-dose vaccine regimen,
did not become HIV infected and did not become
pregnant during the study. Volunteers who attended the
visit outside the scheduled window were included and we
documented retention as a binary outcome (Yes/No).
We selected independent variables based on literature
review of multi-dose vaccine studies that assessed
vaccination completion and/ or retention, and also
included socio-demographic variables as potential
confounders. The independent variables were as follows:
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Socio-demographic characteristics; age, education level
and marital status.
Behavioral characteristics: alcohol use in the past
month (none, once a week or less and daily); being drunk
before sex in the past month (none, sometimes/ most
times and always); drug use in the past month (Yes/ No);
new sexual partner(s) in the past 3 months (Yes /No);
condom use with new sexual partner(s) (Yes/ No);
receiving payment for sex in the past 3 months (Yes/
No); giving payment for sex in the past 3 months (Yes/
No). Payment for sex was in form of money, gifts or
favors.
Clinical characteristics: reported vaginal discharge
syndrome (VDS) in the past 3months (Yes/ No), reported
genital ulcer disease in the past 3months (Yes/ No).
Statistical methods
The study data was double entered in OpenClinica (version
3.1, USA) and analyzed in STATA 14 (StataCorp, College
Station, TX, USA). We summarized volunteer socio
demographic and behavioral characteristics at baseline by
counts and percentages. We estimated the proportion of
volunteers that completed the entire vaccination regimen
(i.e. all three vaccination visits) as number completing all
vaccinations divided by the total number of volunteers
enrolled. We further estimated the proportion of
volunteers that were retained in the study as the number of
volunteers that completed all three vaccinations and also
attended month 12 visit divided by the total number that
were expected to attend (those who received all 3
vaccination doses and were not censored between month 6
and month 12. The two proportions were stratified by the
volunteer baseline characteristics. Data for each volunteer
was divided into observation time points corresponding to
scheduled clinic visits. For each outcome i.e. vaccination
completion and retention, we fitted bivariable Poisson
regression models with time-varying covariates to allow for
intra-individual correlation (because individuals had
multiple records) by using robust standard errors. After
bivariable analyses, two multivariable models were fitted (i)
for retention and (ii) for vaccination completion. Only
factors for which the association attained a statistical
significance at the 20% level using a likelihood ratio test in
a bivariate analysis were considered for the multivariable
model. In the multivariable model, factors were removed
from the model using a backward elimination algorithm if
removing the term did not make the fit of the model
significantly worse at the 5% level on a likelihood ratio test.
Results
Baseline characteristics of FSWs enrolled in the SiVET
study in Kampala, Uganda
We screened 381 volunteers for the study of whom 304
(79.8%) were eligible and 290 (76.1%) enrolled. The
common reasons for not enrolling if eligible were
returning late for the enrolment visit (8) and volunteers
declining enrolment because they thought blood draws
were too frequent (4). The median age of study volunteers
was 27 years (range 18–56 years), 94.5% had attained
primary level education or higher and 70.3% were either
separated or widowed. New sexual partners in the past 3
months were reported by 94.5% of volunteers of whom
79.9% reported always using condoms with new partners.
All except one reported receiving money, gifts or favors in
exchange for sex while 16.2% also reported giving money,
gifts or favors in exchange for sex in the past 3months.
Vaginal discharge syndrome (VDS) and genital ulcer disease
(GUD) were reported by 29.7 and 18.6% respectively.
Table 1 shows volunteer baseline characteristics stratified by
study outcomes.
Factors associated with missing any vaccination visit and
drop out
Of the 290 enrolled women, 239 (82.4%) completed their
3-dose vaccine schedule, and 212 (73.1%) of these also
attended the 12-month study visit. Nine women who did
not complete their vaccination schedule also attended
their 12-month study visit; these were not included in
our final estimate of retention. In total, 230 reached a
study end-point as follows: 7 became HIV infected, 11
became pregnant and 212 completed both the 3-dose
vaccination schedule and the last visit at month 12
giving a retention of 77.9% (212/272).
At adjusted analysis, volunteers who dropped out by
12months were more likely to report GUD symptoms in
the past 3 months (IRR 1.90; 95% CI 1.09–3.32) and be
< 35 years (IRR 6.59; 95% CI 2.11–20.57).
At adjusted analysis, missing any vaccination visit
was associated with being < 35 years (IRR 13.10; 95%
CI 1.89–90.92), reporting GUD symptoms in the past
3 months (IRR 3.02; 95% CI 1.71–5.33) and reporting
consistent condom use with new sexual partners (IRR
2.57; 95% CI 1.10–6.07). We did not find education
level, marital status and substance use (alcohol and
illicit drugs) to be associated with either vaccination
completion or retention. Details are in Table 2.
Discussion
In this cohort study designed to mimic the rigors of an
HIV vaccine trial, retention (completion of the 3-dose
vaccination schedule and the last study visit) was 78%.
Our study is among the few SiVETs done among FSWs
in SSA and reports a slightly lower retention than the
82% retention reported in another SiVET done among
fisher folk in South-western Uganda [20]. HIV vaccine
preparedness studies among other key populations
outside SSA have reported higher retention than ours
[21–23]. The retention we found could be explained by
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the fact that in our setting, FSWs are still criminalized,
discriminated and encounter violence in the community
[14, 15, 24], factors which may in turn hinder health
care seeking and return for study follow up visits. They
are also mobile [16] and this affects retention if study
visits occur while they are out of the study area. We
believe that amidst these challenges, the study team’s
strategies such as phone call reminders, tracing
volunteers for follow up visits and use of appointment
cards as has been done elsewhere were vital in
maintaining study visit attendance in one of the first
SiVET studies to be done among FSWs in SSA. In
addition, our retention results inform a vaccine trial
scenario where data on vaccine efficacy and safety would
only be meaningful if volunteers received all
vaccinations and attended the last study visit for
endpoint review.
Factors associated with retention and vaccination
completion
Studies of hepatitis B vaccination among FSWs and
minority populations in South America have found that
Table 1 Baseline Characteristics of FSWs Enrolled in a simulated vaccine Efficacy Trial, Kampala Uganda (2014–2016)
Variable Sub Category Total n (%) Completed All
Vaccinations n (%)
Completed All Vaccinations and
Month 12 visit n (%)
Overall 290 (100) 239 (82.4) 212 (73.1)
Age (Yrs) 35+ 62 (21.4) 58 (93.6) 55 (88.7)
18–34 228 (78.6) 181 (79.4) 157 (68.9)
Education None 16 (5.5) 12 (75.0) 10 (62.5)
Primary 149 (51.4) 123 (82.6) 112 (75.2)
Secondary or higher 125 (43.1) 104 (83.2) 90 (72.0)
Marital Status Single never married 68 (23.4) 58 (85.3) 52 (76.5)
Married 18 (6.2) 14 (77.8) 13 (72.2)
Separated or widowed 204 (70.3) 167 (81.9) 147 (72.1)
Alcohol use in the past month None 57 (19.7) 44 (77.2) 41 (71.9)
≤ once a week 148 (51.0) 128 (86.5) 110 (74.3)
Daily 85 (29.3) 67 (78.8) 61 (71.8)
Drug use in the past month No 213 (73.4) 177 (83.1) 159 (74.7)
Yes 77 (26.6) 62 (80.5) 53 (68.8)
Drunk before sex in the past month Never 103 (35.5) 86 (83.5) 83 (80.6)
Sometimes/ most times 170 (58.6) 140 (82.4) 119 (70.0)
Always 17 (5.9) 13 (76.5) 10 (58.8)
Reported VDS in past 3 months No 204 (70.3) 174 (85.3) 154 (75.5)
Yes 86 (29.7) 65 (75.6) 58 (67.4)
Reported GUD in past 3 months No 236 (81.4) 200 (84.8) 179 (75.9)
Yes 54 (18.6) 39 (72.2) 33 (61.1)
Number of Sexual partners in
past 3 months
0–2 14 (4.9) 11 (78.6) 10 (71.4)
0–3 61 (21.0) 53 (86.9) 50 (82.0)
≥ 6 215 (74.1) 175 (81.4) 152 (70.7)
New sexual partner in past 3 months No 16 (5.5) 12 (75.0) 10 (62.5)
Yes 274 (94.5) 227 (82.9) 202 (73.7)
Condom use with new partner(s) Never 3 (1.1) 3 (100) 3 (100)
Sometimes/ most times 52 (19.0) 48 (92.3) 42 (80.8)
Always 219 (79.9) 176 (80.4) 157 (71.7)
Receiving payment for sex in
past 3 months
No 1 (0.3) 1 (100) 1 (100)
Yes 289 (99.7) 238 (82.4) 211 (73.0)
Giving payment for sex in
past 3 months
No 243 (83.8) 202 (83.1) 181 (74.5)
Yes 47 (16.2) 37 (78.7) 31 (66.0)
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less than one third of volunteers complete the
vaccination schedule [25, 26]. In our study women aged
< 35 years were less likely to complete the vaccination
schedule or be retained with the risk of non-retention
being higher among the youngest age group (18–24
years). Similarly, in a study done among at-risk youth
who were randomized to a standard 0, 1 and 6months’
hepatitis B vaccination schedule versus an accelerated 0,
1 and 2months’ schedule, younger volunteers were less
likely to complete a vaccination schedule [27]. These
findings are corroborated by work done in the HIV
vaccine field including: HIV vaccine preparedness
cohorts, and clinical trials of both vaginal microbicides
and candidate HIV vaccines [28–30] and yet younger
age has been associated with increased risk of HIV
acquisition [31, 32]. In the broader context of HIV,
studies of the “test and treat” intervention among HIV
positive women from the same cohort as the SiVET
study group [33] and elsewhere [34, 35] have found that
younger people are less likely to initiate prompt anti-
retroviral therapy (ART). Younger women from high
risk communities are vulnerable and experience a
Table 2 Factors associated with missing any one-vaccination visit, and non-retention in the SiVET study
Variable Sub Category Missing any one vaccination visit Non retention
Unadjusted
IRR (95%CI)
LRT-p
value
Adjusted
IRR (95%CI)
Unadjusted
IRR (95%CI)
LRT-p
value
Adjusted
IRR (95%CI)
Age (years) 35+ 1.00 0.013 1.00 1.00 0.002 1.00
18–34 3.59 (1.31–9.83) 13.10 (1.89–90.92) 3.24 (1.52–6.88) 6.59 (2.11–20.57)
Education level None 1.00 0.666 1.00 0.492
Primary 0.67 (0.24–1.86) 0.61 (0.27–1.37)
Secondary or higher 0.62 (0.22–1.74) 0.67 (0.30–1.50)
Marital Status Single never married 1.00 0.669 1.0 0.714
Married 1.62 (0.53–4.93) 1.32 (0.51–3.40)
Separated or
widowed
1.27 (0.63–2.54) 1.24 (0.72–2.12)
Alcohol use in the past
month
None 1.00 0.226 1.00 0.327
Once a week
or less
0.59 (0.31–1.14) 0.73 (0.42–1.25)
Daily 0.91 (0.46–1.78) 1.02 (0.58–1.80)
Drug use in the past month No 1.00 0.841 1.00 0.295
Yes 1.06 (0.58–1.94) 1.28 (0.80–2.05)
Drunk before sex in past
month
Never 1.00 0.903 1.00 0.973
Sometimes /most
times
0.98 (0.56–1.71) 1.03 (0.66–1.61)
Always 0.72 (0.17–2.99) 0.91 (0.29–2.87)
Reported VDS in past 3
months
No 1.00 0.217 1.00 0.998
Yes 1.42 (0.81–2.45) 0.99 (0.62–1.62)
Reported GUD in past 3
months
No 1.00 0.003 1.00 1.00 0.012 1.00
Yes 2.44 (1.36–4.37) 3.02 (1.71–5.33) 1.58 (0.93–2.68) 1.90 (1.09–3.32)
Number of sexual partners 0–2 1.00 0.866 1.00 0.427
3–5 1.04 (0.31–3.53) 0.71 (0.29–1.72)
6+ 1.22 (0.40–3.71) 1.06 (0.51–2.21)
New sexual partner in
past 3 months
No 1.00 0.481 1.00 0.268
Yes 0.73 (0.31–1.74) 0.71 (0.38–1.31)
Condom use with new
partner(s)
Never/Inconsistently 1.00 0.03 1.00 1.00 0.060 1.00
Consistently 2.06 (0.82–5.20) 2.57 (1.10–6.07) 2.08 (0.97–4.47) 2.04 (1.00–4.15)
Giving payment for sex
in past 3 months
No 1.00 0.380 1.00 0.204
Yes 1.35 (0.69–2.63) 1.42 (0.83–2.42)
Multivariable analysis adjusted for age, genital ulcer disease in the past 3 months and condom use with a new partner(s)
Data in bold are statistically significant
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greater degree of unequal power relations, gender
inequities, exploitation, limited social support and
intimate partner violence when compared to older
women [36, 37] who also make the working
environment uncomfortable for the younger ones by
patronizing, bullying and exploiting them [36, 38]. This
may affect their ability to engage with health services
[39]. FSWs also work through pimps and middlemen, a
group of stakeholders who usually control and make
decisions for them, limit their independence [40, 41] and
subsequently freedom to make the required study visits.
The stakeholders are usually influential community
members or those who hold power and vary by
community. They include but are not limited to older
FSWs, middlemen and community leaders, and have an
important role in empowering younger women.
Empowering young FSWs to participate more in HIV
prevention programs as peer leaders and decision makers
has been identified as a need [42] and may improve
retention and vaccination completion in future HIV
vaccine efficacy trials.
Volunteers who reported GUD in the past 3 months
were less likely to complete the vaccination schedule or
be retained. Studies among high risk women attending
primary health care facilities have not found an
association between STIs and vaccination completion
[43], however elsewhere, STIs have been associated with
Hepatitis B vaccination completion among MSM [44,
45]. Risk behavior such as injection drug use and
multiple sexual partners have been associated with low
completion of multi-dose vaccine schedules [25, 45].
GUD is a surrogate marker of risky sexual behavior yet
low risk perception may lead to complacency with
disease prevention and health promotion interventions;
GUD has long been understood as a risk factor for HIV
acquisition as well [46, 47]. Population based surveys
done in different settings and age groups give mixed
results on the association between risky sexual behavior
and uptake of health interventions [48, 49]. Volunteers
who report genital symptoms such as GUD need close
follow up to ensure high retention in future trials.
Our finding that women who used condoms consistently
with new sexual partners were less likely to complete the
vaccination schedule, though unexpected, is similar to
findings from two FSW cohort studies in Kenya and China
that assessed attrition among HIV negative volunteers [50,
51]. On the contrary, Shokoohi et al. have reported
inconsistent condom use among HIV negative women to
be associated with a lower likelihood of recent HIV testing,
a finding that is consistent with high risk behavior [52].
We believe that women may have felt protected by
consistent condom use with new partners and were
therefore less keen to attend study vaccination visits.
Hepatitis B vaccine being used to simulate an HIV vaccine
product may not have been perceived beneficial for HIV
prevention like condoms which actually protect against
HIV infection if used consistently. A survey of acceptability
of future HIV vaccines has shown that acceptability
increases if perceived benefits of the vaccine are higher
[53]. Volunteers who report consistent condom use may
miss vaccination visits in future HIV vaccine efficacy trials
but also those who adhere to vaccination visits may engage
in risk behavior such as inconsistent condom use or
multiple sexual partnerships (Risk Compensation) as has
been reported elsewhere [54, 55]. Volunteers who report
consistent condom use need on-going education and
counselling to enable vaccination completion in future
HIV vaccine trials.
Limitations and strengths
This study used a licensed commercially available vaccine
in lieu of an experimental product, thus observed
outcomes may differ from what would be observed in a
trial using a real HIV vaccine investigational product with
unknown long-term safety profile. The SiVET enrolled
from an existing cohort; the women who accept to get
enrolled and access services in the general FSW cohort
may be different from those who decline and remain in
the community thereby introducing selection bias in the
study sample and affecting generalizability of findings.
The study procedures however were designed to mimic
the rigors of an efficacy trial hence giving us more
knowledge about feasibility of a future vaccine efficacy
trial. Our retention findings are granular enough to
provide information not only on last visit attendance but
also completion of the vaccination schedule, an outcome
important to demonstrate vaccine efficacy.
Conclusions
FSWs in Kampala are at substantial risk of HIV infection
and are willing to be enrolled in HIV vaccine and
prevention research; however, younger FSWs may be
harder to retain. There is a need to design strategies that
overcome the social and community barriers faced by
younger FSWs in order to improve participation in future
vaccine efficacy trials. Such strategies would involve
sensitization of influential and powerful community
stakeholders about the need for young FSWs to participate
in research and empowering the young FSWs to be
decision makers in HIV prevention. Factors associated with
high-risk behavior among FSWs such as STI symptoms
also lead to lower retention and vaccination completion.
Volunteers who report STI symptoms such as GUD need
tracing not only for treatment but also for follow up to
ensure high retention in future vaccine trials.
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